

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	Unknown
Gender:	Unknown
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Acetylcholine Receptor Antibody Reflexive Panel

ARUP	test	code	2001571	

Acetylcholine Binding Antibody	85.0 r	nmo]/L	Н	(Ref Interval: 0.0-0.4)
	Acetylch Sample v	noline rece vill reflex	eptor bindi to modula	ng antibody result is positive. ting antibody testing.
	INTERPRE	TIVE INFOR	MATION: AC	etylcholine Binding Ab
			0.0 - 0.4 0.5 nmol/	nmol/L L or greater
	(MG) exp which ca antibodi loss of acetylch contract resultir closely percent	oress antib on be divid es. Bindin AChR. Bloc holine to t tion. Modul og in loss with clini of individ	oodies to t led into bi og antibody cking antib che recepto ating anti of AChR ex cal severi luals with	of patients with myasthenia gravis the acetylcholine receptor (AChR), nding, blocking, and modulating can activate complement and lead to ody may impair binding of or, leading to poor muscle body causes receptor endocytosis pression, which correlates most ty of disease. Approximately 10-15 confirmed myasthenia gravis have no l, or modulating antibodies.
	determir approved performe	ed by ARUF by the US	P Laborator 5 Food and A certifie	its performance characteristics ies. It has not been cleared or Drug Administration. This test was d laboratory and is intended for
Acetylcholine Blocking Antibody	90 %	Н		(Ref Interval: 0-26)

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



INTERPRETIVE INFORMATION: Acetylcholine Blocking Ab

Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Acetylcholine Receptor Modulating Antibody

ARUP test code 0099521

Acetylcholine Modulating Antibody	50 % H (Ref Interval: <=45) INTERPRETIVE INFORMATION: Acetylcholine Modulating Ab
	Negative 0-45 percent modulating Positive 46 percent or greater modulating
	Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
	This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 24-100-114346 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 3 | Printed: 4/9/2024 2:16:04 PM 4848



VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Acetylcholine Binding Antibody	24-100-114346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Acetylcholine Blocking Antibody	24-100-114346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Acetylcholine Modulating Antibody	24-100-114346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Sati Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 24-100-114346 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 3 of 3 | Printed: 4/9/2024 2:16:04 PM 4848